Treats Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE). ANDA 215732, held by Hainan Poly. Esomeprazole Sodium.
As of Nov 16, 2026, ANDA 215732 (Esomeprazole Sodium), held by Hainan Poly, was first approved by FDA on Feb 10, 2022, with 2 approved supplements and 0 published complete response letters.
Esomeprazole sodium for injection is a proton pump inhibitor (PPI) indicated for the: Short-term treatment of Gastroesophageal Reflux Disease (GERD) with erosive esophagitis (EE) in adults and pediatric patients 1 month to 17 years of age, as an alternative to oral therapy when oral esomeprazole is not possible or appropriate. Risk reduction of rebleeding of gastric or duodenal ulcers following therapeutic endoscopy for acute bleeding gastric or duodenal ulcers in adults. 1.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Feb 10, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Esomeprazole SodiumEQ 40MG BASE/VIAL · injectable;intravenous | Esomeprazole Sodium | Rx |
| Feb 8, 2024 | Supplement 2Labeling · Standard review | Approved | None posted |
| Feb 1, 2023 | Supplement 1Labeling · Standard review | Approved | None posted |
| Feb 10, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters